

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Innovent

信達生物製藥

INNOVENT BIOLOGICS, INC.

(Incorporated in the Cayman Islands with Limited Liability)

(Stock Code: 1801)

INSIDE INFORMATION ANNOUNCEMENT ENTERING INTO STRATEGIC COLLABORATION WITH LILLY TO DEVELOP NEW MEDICINES GLOBALLY IN ONCOLOGY AND IMMUNOLOGY

This announcement is made by Innovent Biologics, Inc. (the “**Company**” and “**Innovent**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The board of directors (the “**Directors**”) of the Company (the “**Board**”) is pleased to announce that the Company, together with its wholly-owned subsidiaries Innovent Biologics (Suzhou) Co., Ltd., Fortvita Biologics (Singapore) Pte. Ltd, Fortvita Biologics Inc, and Fortvita Biologics (USA), Inc, entered into a strategic collaboration with Eli Lilly and Company (“**Lilly**”), to advance novel medicines in oncology and immunology. This agreement marks the seventh collaboration between the two groups, deepening a longstanding and productive partnership to deliver new medicines for patients worldwide. The partnership’s unique structure also establishes a new model for Innovent to accelerate the global development of its innovative pipeline.

Under the collaboration, the companies will leverage their complementary strengths to accelerate global development of novel medicines. Innovent, drawing on its robust antibody technology platforms and efficient clinical execution, will lead the development of programs from concept through clinical proof-of-concept (Phase 2 clinical trial completion) in China. The agreement grants Lilly an exclusive worldwide license to develop and commercialize the programs worldwide outside Greater China, while Innovent retains rights in Greater China.

Under the terms of the agreement, Innovent will receive a US\$350 million upfront payment and is eligible to receive development, regulatory and commercial milestone payments totaling up to approximately US\$8.5 billion contingent upon the achievement of certain future events. Additionally, Innovent will be eligible for tiered royalties on net sales of each product outside of Greater China.

The Company believes that this strategic collaboration moves beyond traditional licensing to create a seamless, end-to-end innovation ecosystem that combines Innovent's agile discovery and early-stage development engine with Lilly's extensive global scale, and creates a highly efficient model for cross-border synergy. This partnership validates Innovent's Research and Development capabilities and allows the Company to accelerate the translation of the scientific discoveries into impactful global medical solutions, with the ultimate goal of bringing world-class medicines to patients across the globe.

Forward-Looking Statements

This announcement may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to the Company, are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions.

By Order of the Board
Innovent Biologics, Inc.
Dr. De-Chao Michael Yu
Chairman and Executive Director

Hong Kong, China,
February 8, 2026

As at the date of this announcement, the Board comprises Dr. De-Chao Michael Yu as Chairman and Executive Director and Mr. Ronald Hao Xi Ede and Ms. Qian Zhang as Executive Directors, and Dr. Charles Leland Cooney, Ms. Joyce I-Yin Hsu, Mr. Gary Zieziula, Dr. Shun Lu, Mr. Shuyun Chen and Dr. Stephen A. Sherwin as Independent Non-executive Directors.